Hangzhou Tigermed Consulting Co., Ltd Stocks

Hangzhou Tigermed Consulting Co., Ltd. functions as a prominent Contract Research Organization (CRO), delivering its services throughout the People's Republic of China and on an international scale. The company structures its comprehensive offerings primarily within two key segments: Clinical Trial Solutions, and Clinical-related and Laboratory Services. Within these segments, Tigermed provides a broad spectrum of support. This includes critical regulatory services such as submission and approval assistance, specialized medical translation, and expert consultation on Good Manufacturing Practice (GMP). Additionally, it delivers extensive clinical development services, encompassing medical science guidance, execution of early and late-phase clinical trials, medical monitoring, meticulous project management, efficient patient recruitment strategies, and robust quality management systems. Its biometrics division is adept at handling data management, biostatistics, and sophisticated statistical programming. Furthermore, integrated technological support spans areas like site management, pharmacovigilance, independent audit and training programs, medical imaging solutions, advanced clinical trial system implementations, central laboratory services, pre-clinical research, and support for research hospitals. Tigermed also possesses specialized expertise in medical device and in vitro diagnostics (IVD) services. This entails device testing, regulatory submissions, clinical evaluations and trials, GMP certification assistance, preparation for EU MDR and IVDR compliance, and various value-added offerings. Beyond this, the company conducts post-marketing studies, generates real-world evidence (RWE), and manages clinical trials specifically for vaccines. Established in 2004, Hangzhou Tigermed Consulting Co., Ltd. maintains its headquarters in Hangzhou, People's Republic of China.